Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Affiliations

• ¹ TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
• ⁴ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Division of Melanoma, Sarcoma, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
• ⁷ Department of Surgery, Guthrie Courtland Medical Center, Courtland, NY, USA.
• ⁸ Immunai, New York, NY, USA.
• ⁹ Department of Surgery, University of Rochester, Rochester, NY, USA.
• ¹⁰ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹¹ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹² Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹³ Department of Surgery, Washington University in St Louis, St Louis, MO, USA.
• ¹⁴ Moffitt Cancer Center, Tampa, FL, USA.
• ¹⁵ AstraZeneca, Gaithersburg, MD, USA.
• ¹⁶ Clinical Development and Analytics, Novartis Pharmaceuticals, East Hanover, NJ, USA.
• ¹⁷ Novartis Pharma, Basel, Switzerland.
• ¹⁸ Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
• ¹⁹ Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
• ²⁰ Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ²¹ Department of Pathology, University of California, San Francisco, CA, USA.
• ²² Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
• ²³ Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ²⁴ Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
• ²⁵ TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].
• ²⁶ TRACTION Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].
• ²⁷ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].
• ²⁸ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. [email protected].